相关实验视频
Updated: Jun 25, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.7K
使用前列腺癌指导式主动监测的患者的长期结果
Lisa F Newcomb1,2, Jeannette M Schenk1, Yingye Zheng3
1Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
JAMA
|May 30, 2024
概括
积极监测有利风险的前列腺癌是有效的,49%的男性在10年内保持无进展. 这种治疗策略表明转移率和前列腺癌死亡率较低.
科学领域:
- 泌尿外科
- 癌症学
- 临床研究
背景情况:
- 基于协议的积极监测对于管理有利风险的前列腺癌至关重要.
- 需要长期的瘤结果数据来为临床决策提供信息.
研究的目的:
- 评估正在积极监测前列腺癌的患者的长期瘤结果.
- 在多中心,协议指导的队列中描述结果.
主要方法:
- 在2008年启动的前性队列研究 (加拿大前列腺活跃监测研究).
- 在10个北美中心招募了2,155名前列腺癌风险较高的男性.
- 随访至2022年8月,评估生物检查重新分类,治疗,转移和死亡率等结果.
主要成果:
- 在10年后,49%的患者仍然没有进展或治疗.
- 活检级别的重新分类发生率为43%,治疗发生率为49%.
- 在10年内发生的转移性癌症为1. 4%,前列腺癌死亡率为0. 1%.
结论:
- 积极监测是有利风险前列腺癌的有效管理策略.
- 随访期间的晚期进展或治疗与更糟糕的结果无关.
- 这项研究支持对精选的前列腺癌患者的积极监测.
相关概念视频
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K